Pyxis Oncology, Inc. Stock Issued During Period, Value, Restricted Stock Award, Gross
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Pyxis Oncology, Inc. stock issued during period, value, restricted stock award, gross for the quarter ending 2023-12-31 was -$55.00K.
- Pyxis Oncology, Inc. stock issued during period, value, restricted stock award, gross for the quarter ending 2023-09-30 was -$393.00K.
- Pyxis Oncology, Inc. stock issued during period, value, restricted stock award, gross for the quarter ending 2023-06-30 was $1.00K.
- Pyxis Oncology, Inc. stock issued during period, value, restricted stock award, gross for the quarter ending 2023-03-31 was $2.00K, a 100.00% increase year-over-year.
- Pyxis Oncology, Inc. stock issued during period, value, restricted stock award, gross for fiscal 2023 was -$445.00K.
- Pyxis Oncology, Inc. stock issued during period, value, restricted stock award, gross for fiscal 2021 was $3.00K, a 70.00% decline from fiscal 2020.
- Pyxis Oncology, Inc. stock issued during period, value, restricted stock award, gross for fiscal 2020 was $10.00K.
| Period end | Stock Issued During Period, Value, Restricted Stock Award, Gross 3 month | Stock Issued During Period, Value, Restricted Stock Award, Gross 12 month |
|---|---|---|
| 2023-12-31 | -$55.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$445.00K 10-K · filed 2024-03-21 |
| 2023-09-30 | -$393.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $1.00K 10-Q · filed 2024-08-14 | |
| 2023-03-31 | $2.00K 10-Q · filed 2023-08-11 | |
| 2022-03-31 | $1.00K 10-Q · filed 2023-08-11 | $12.00K derived: sum of 4 quarters · filed 2023-08-11 |
| 2021-12-31 | -$6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $3.00K 10-K · filed 2023-03-22 |
| 2021-09-30 | $14.00K 10-Q · filed 2022-11-01 | |
| 2021-06-30 | $3.00K 10-Q · filed 2022-08-15 | |
| 2021-03-31 | $3.00K 10-Q · filed 2022-08-15 | |
| 2020-12-31 | $10.00K 10-K · filed 2022-03-29 | |
| 2020-09-30 | $3.00K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $1.00K 10-Q · filed 2021-11-15 | |
| 2020-03-31 | $1.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |